Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study
Authors:
- Christine GaabCGChristine Gaab
- Jonas E. AdolphJAJonas E. Adolph
- Stephan TippeltSTStephan Tippelt
- Ruth MikaschRMRuth Mikasch
- Denise ObrechtDODenise Obrecht
- Martin MynarekMMMartin Mynarek
- Stefan RutkowskiSRStefan Rutkowski
- Stefan M. PfisterStefan M. Pfister
- Till MildeTMTill Milde
- Olaf WittOWOlaf Witt
- Brigitte BisonBBBrigitte Bison
- Monika Warmuth-MetzMWMonika Warmuth-Metz
Open Access
Abstract
Recurrent medulloblastomas are associated with survival rates n = 30/93) found mainly in molecular subgroup 3 were associated with markedly worse median PFS (HR: 2.34) and OS (HR: 3.26) in regression analyses. A significant survival advantage was found for the use of volume-reducing surgery as well as radiotherapy. Intravenous chemotherapy with carboplatin and etoposide (ivCHT, n = 28/93) showed improved PFS and OS data and the best objective response rate (ORR) was 66.7% compared to oral temozolomide (oCHT, n = 47/93) which was 34.8%. Intraventricular (n = 43) as well as high-dose chemotherapy (n = 17) at first relapse was not related to a significant survival benefit. Although the results are limited due to a non-randomized study design, they may serve as a basis for future treatment decisions in order to improve the patients’ survival.Keywords
Funding Information
- German Children Cancer Foundation (DKS 2006.01, DKS 2008.07, DKS 2012.03, DKS 2015.02, DKS 2017.12, DKS 2020.02)
This publication has 40 references indexed in Scilit:
- Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor studyNeuro-Oncology, 2013
- Clonal selection drives genetic divergence of metastatic medulloblastomaNature, 2012
- Role of high‐dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumorsPediatric Blood & Cancer, 2010
- High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastomaNeuro-Oncology, 2010
- Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastomaNeuro-Oncology, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- High‐dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapyCancer, 2007
- Pharmacokinetics Following Intraventricular Administration of Chemotherapy in Patients with Neoplastic MeningitisClinical Pharmacokinetics, 2005
- Efficacy of Vincristine and Cyclophosphamide in the Therapy of Recurrent MedulloblastomaNeurosurgery, 1986
- Heuristic modeling of drug delivery to malignant brain tumorsJournal of Pharmacokinetics and Biopharmaceutics, 1980